Breaking News Instant updates and real-time market news.

2022-12-02 13:17:02 $NSD NASDAQ Market Internals / + 13:17 12/02/22 12/02 13:17 12/02/22 13:17	NASDAQ market internals summary Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 2043 / Declining Issues: 2302 -- for a ratio of 0.9 to 1. Advancing Volume: 1,093,434,000 / Declining Volume: 1,308,122,000 -- for a ratio of 0.8 to 1. New 52-Week Highs: 67 / New 52-Week Lows: 124.

2022-12-02 13:17:02

$NSD

NASDAQ Market Internals

/ +

13:17

12/02/22

12/02

13:17

12/02/22

13:17

NASDAQ market internals summary

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 2043 / Declining Issues: 2302 -- for a ratio of 0.9 to 1. Advancing Volume: 1,093,434,000 / Declining Volume: 1,308,122,000 -- for a ratio of 0.8 to 1. New 52-Week Highs: 67 / New 52-Week Lows: 124.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Verses, SimWell partner to enhance digital twin stimulations with KOSMOS » 08:17 03/29/23 03/29 08:17 03/29/23 08:17 VRSSF Verses Technologies / + VERSES Technologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News VRSSF Verses Technologies / + 03/22/23 Verses Technologies closes second tranche of convertible debenture financing 03/01/23 Verses closes $5M tranche, announces upsize of convertible debenture financing 02/27/23 Verses Technologies announces convertible debenture financing up to C$5M 02/23/23 Verses Technologies announces General Intelligent Agent, codenamed GIA
Hot Stocks	Crispr Therapeutics announces departure of board member » 08:16 03/29/23 03/29 08:16 03/29/23 08:16 CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) CRISPR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact 03/13/23 Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed 12/27/22 Cathie Wood's ARK Investment bought 10.8K shares of Crispr Therapeutics today 12/19/22 Crispr Therapeutics appoints Harding as SVP, Head of Business Development CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/21/23 Bernstein Crispr Therapeutics initiated with a Market Perform at Bernstein 03/18/23 Citi Crispr Therapeutics price target lowered to $55 from $63 at Citi 03/17/23 Bryan Garnier Crispr Therapeutics initiated with a Buy at Bryan Garnier 03/06/23 Baird Baird starts Crispr at Neutral with strong launch priced in CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y 04/03/23 The Future of Oncology Virtual Symposium CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/21/23 Crispr Therapeutics options imply 4.4% move in share price post-earnings 02/14/23 Crispr Therapeutics options imply 4.9% move in share price post-earnings 01/05/23 Crispr Therapeutics call volume above normal and directionally bullish
Hot Stocks	G Medical Innovations enters into agreement with AdventHealth Central Florida » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) G Medical Innovations… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) 03/27/23 G Medical Innovations, MiCare Path announce joint collaboration 02/13/23 G Medical Innovations receives patent from USPTO for vital sign sensors 01/30/23 G Medical Innovations granted patent by USPTO for vital signs sensors 12/05/22 G Medical Innovations receives two U.S. patents for monitoring products
Hot Stocks	Caribou initiates dose expansion portion of CB-010 ANTLER Phase 1 trial » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 08:12 Today Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Hot Stocks	First Solar announces facility in India awarded financial incentives » 08:13 03/29/23 03/29 08:13 03/29/23 08:13 FSLR First Solar $210.01 / +0.08 (+0.04%) First Solar announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options FSLR First Solar $210.01 / +0.08 (+0.04%) 03/01/23 Origis Energy enters agreeent with First Solar for 2 GW of modules 02/28/23 First Solar announces Lightsource bp places multi-year order for 4 GW 01/12/23 First Solar completes sale of 141 MW Luz del Norte power plant to Toesca 12/19/22 First Solar to replace Fortune Brands in S&P 500 at open on 12/19 FSLR First Solar $210.01 / +0.08 (+0.04%) 03/23/23 Barclays First Solar price target raised to $230 from $162 at Barclays 03/15/23 Credit Suisse First Solar price target raised to $163 from $152 at Credit Suisse 03/14/23 Argus First Solar price target raised to $261 from $176 at Argus 03/09/23 Citi First Solar transferred with Neutral rating at Citi FSLR First Solar $210.01 / +0.08 (+0.04%) 02/28/23 First Solar sees FY23 EPS $7.00-$8.00, consensus $4.77 02/28/23 First Solar reports Q4 EPS (7c), consensus (15c) 02/28/23 Notable companies reporting after market close 10/27/22 First Solar reports Q3 EPS (46c), consensus (27c) FSLR First Solar $210.01 / +0.08 (+0.04%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports FSLR First Solar $210.01 / +0.08 (+0.04%) 03/06/23 What You Missed This Week in EVs and Clean Energy 03/03/23 What You Missed On Wall Street On Friday 03/03/23 What You Missed On Wall Street This Morning 02/28/23 Fly Intel: After-Hours Movers FSLR First Solar $210.01 / +0.08 (+0.04%) 03/08/23 Unusually active option classes on open March 8th 03/06/23 Early notable gainers among liquid option names on March 6th 03/03/23 Early notable gainers among liquid option names on March 3rd 03/01/23 Early notable gainers among liquid option names on March 1st
Hot Stocks	Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Recommendations	Viking Therapeutics price target raised to $25 from $15 at Maxim » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735 03/28/23 Viking Therapeutics jumps 32% to $12.06 after Phase 1 VK2735 trial results 03/28/23 Viking Therapeutics announces results from Phase 1 trial of VK2735 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 06:15 Today Raymond James Viking Therapeutics price target raised to $35 from $12 at Raymond James 03/28/23 BTIG Viking Therapeutics price target raised to $31 from $20 at BTIG 03/28/23 Oppenheimer Viking Therapeutics price target raised to $30 from $20 at Oppenheimer 03/28/23 Stifel Stifel reiterates Buy on Viking Therapeutics, raises price target to $25 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish
Hot Stocks	Enphase Energy launches new IQ8 microinverters in France, the Netherlands » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 ENPH Enphase Energy $193.50 / -2.28 (-1.16%) Enphase Energy announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/20/23 Enphase Energy expands IQ8 microinverter deployments in Virginia 03/13/23 Enphase Energy expands IQ8 microinveter deployments in Utah 03/06/23 Enphase Energy expands IQ8 microinverter deployments in Illinois 02/26/23 Fly Intel: Top five weekend stock stories ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/22/23 Susquehanna Enphase upgraded to Positive on recent pullback at Susquehanna 03/22/23 Susquehanna Enphase Energy upgraded to Positive from Neutral at Susquehanna 03/20/23 Raymond James Enphase Energy upgraded to Outperform from Market Perform at Raymond James 03/09/23 Citi Enphase Energy transferred with Buy rating at Citi ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/07/23 Enphase Energy sees Q1 revenue $700M-$740M, consensus $690.46M 02/07/23 Enphase Energy reports Q4 EPS $1.51, consensus $1.24 02/07/23 Notable companies reporting after market close 10/25/22 Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/25/23 Corning, Enphase among key U.S. Clean Energy players, Barron's says ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/23/23 Early notable gainers among liquid option names on March 23rd 03/20/23 Early notable gainers among liquid option names on March 20th 03/06/23 Early notable gainers among liquid option names on March 6th 02/27/23 Early notable gainers among liquid option names on February 27th
Hot Stocks	Akari announces Poland, U.K. approve new manufacturing process for nomacopan » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AKTX Akari Therapeutics / + Akari Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research AKTX Akari Therapeutics / + 02/21/23 Akari Therapeutics presents case study from Phase 3 Part A trial of nomacopan 02/15/23 Akari announces pre-clinical development progress toward IND for GA treatment 02/13/23 Akari Therapeutics announces acceleration of Phase 3 trial of nomacopan 11/10/22 Akari Therapeutics announces FDA granted RPDD to nomacopan AKTX Akari Therapeutics / + 12/05/22 H.C. Wainwright Akari Therapeutics initiated with a Buy at H.C. Wainwright 11/01/22 Alliance Global Partners Akari Therapeutics initiated with a Buy at Alliance Global Partners
Upgrade	Anhui Conch Cement upgraded to Neutral from Sell at Goldman Sachs » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) 11/15/22 HSBC Anhui Conch Cement upgraded to Buy from Hold at HSBC 08/28/22 Goldman Sachs Anhui Conch Cement downgraded to Sell from Neutral at Goldman Sachs

Hot Stocks	Kala Pharmaceuticals appoints Francis Mah as chief medical advisor » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) Kala Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/27/23 Kala announces safety update from Cohort 1 of CHASE Phase 2b trial 02/14/23 Kala recruiting for study of KPI-012 in participants with PCED 01/19/23 Kala Pharmaceuticals falls 10% to $15.90 after equity offering 12/30/22 Kala Pharmaceuticals trading resumes KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/06/23 H.C. Wainwright Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright 12/29/22 Wedbush IND acceptance sets up Kala for execution year in 2023, says Wedbush 11/09/22 Wedbush Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush 05/24/22 H.C. Wainwright Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/03/23 Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year 11/08/22 Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 01/19/23 Fly Intel: After-Hours Movers 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 Fly Intel: After-Hours Movers 04/24/23 Kala Pharmaceuticals, Inc.
Hot Stocks	NV5 awarded $11M essential infrastructure projects in California, New Mexico » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 NVEE NV5 Global $100.90 / +0.02 (+0.02%) NV5 Global announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVEE NV5 Global $100.90 / +0.02 (+0.02%) 03/13/23 NV5 Global announces $11M in engineering, planning awards 03/06/23 NV5 Global announces Axim Geospatial awarded $9M in national security contracts 03/02/23 NV5 Global acquires Gaudet Associates 02/23/23 NV5 Global announces acquisition of Axim Geospatial NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/24/23 Baird NV5 Global price target lowered to $130 from $150 at Baird 08/05/22 Lake Street NV5 Global price target raised to $175 from $136 at Lake Street NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/23/23 NV5 Global reports Q4 EPS $1.21 , consensus $1.57 11/03/22 NV5 Global reports Q3 adjusted EPS $1.50, consensus $1.45
Hot Stocks	DoubleDown announces results of 2023 Annual General Meeting » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 DDI DoubleDown $8.09 / +0.08 (+1.00%) DoubleDown Interactive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research DDI DoubleDown $8.09 / +0.08 (+1.00%) 01/11/23 DoubleDown to acquire i-Gaming company SuprNation for $35M 12/28/22 DoubleDown announces results of EGM held on December 28 DDI DoubleDown $8.09 / +0.08 (+1.00%) 09/15/22 Macquarie DoubleDown initiated with an Outperform at Macquarie 07/11/22 B. Riley Investors have overlooked DoubleDown, says B. Riley 06/28/22 B. Riley DoubleDown price target lowered to $20 from $30 at B. Riley
Initiation	Engie Brasil initiated with an Outperform at Scotiabank » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) Scotiabank analyst Renato… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) 03/07/23 UBS Engie Brasil upgraded to Buy from Neutral at UBS 01/10/23 JPMorgan Engie Brasil upgraded to Overweight from Neutral at JPMorgan 10/14/22 JPMorgan Engie Brasil upgraded to Neutral from Underweight at JPMorgan 08/08/22 JPMorgan Engie Brasil downgraded to Underweight from Neutral at JPMorgan
Recommendations	LuxUrban Hotels price target raised to $7 from $6 at Maxim » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 02/16/23 LuxUrban Hotels announces preferred U.S.hotel partnership with NusaTrip 02/08/23 LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms 12/02/22 LuxUrban Hotels names Jimmie Chatmon COO 12/01/22 LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 12/12/22 Maxim LuxUrban Hotels initiated with a Buy at Maxim LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 01/18/23 LuxUrban Hotels affirms FY22 net rental revenue and EBITDA guidance
Hot Stocks	Rapt Therapeutics announces initiation of Phase 2a trial of RPT193 » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) RAPT Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/10/23 Rapt Therapeutics says $2M of cash held at Silicon Valley Bank 12/08/22 Rapt Therapeutics reports Phase 1/2 results of FLX475 in advanced cancer 11/17/22 Rapt Therapeutics falls 7% to $19.70 after $75M common stock offering RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/15/23 Capital One Rapt outlook 'remains steady' despite shift in timeline, says Capital One 03/15/23 Cantor Fitzgerald Rapt Therapeutics price target lowered to $40 from $44 at Cantor Fitzgerald 03/15/23 H.C. Wainwright Rapt Therapeutics price target lowered to $43 from $50 at H.C. Wainwright 01/04/23 Guggenheim Rapt Therapeutics initiated with a Buy at Guggenheim RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/14/23 Rapt Therapeutics reports Q4 EPS (64c), consensus (66c) 11/10/22 Rapt Therapeutics reports Q3 EPS (63c), consensus (67c) 18 Nov RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/16/23 Biotech Alert: Searches spiking for these stocks today 11/17/22 Fly Intel: After-Hours Movers
Hot Stocks	Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) Harmony Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' 01/09/23 Novavax names John Jacobs as new CEO, succeeding Stanley Erck 01/06/23 Harmony Biosciences CEO John Jacobs stepping down 11/15/22 Harmony Biosciences director sells $9.12M in common stock HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Mizuho Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 03/28/23 Raymond James Raymond James says buy Harmony on weakness after 'low quality' short report 02/22/23 Mizuho Harmony Biosciences price target lowered to $60 from $70 at Mizuho 01/04/23 Piper Sandler Harmony Biosciences price target raised to $70 from $62 at Piper Sandler HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 02/21/23 Harmony Biosciences reports Q4 non-GAAP EPS $1.01, consensus 58c 11/01/22 Harmony Biosciences reports Q3 non-GAAP EPS 95c vs 41c last year HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Scorpion: Filing Citizen's Petition to request withdrawal of Harmony drug 03/28/23 Scorpion Capital issues investigative report on Harmony Biosciences HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/28/23 Harmony plunges as Scorpion seeks FDA withdrawal of Wakix approval 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Pacira announces FDA clearance of sNDA for EXPAREL label » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PCRX Pacira $39.93 / -0.15 (-0.37%) Pacira BioSciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PCRX Pacira $39.93 / -0.15 (-0.37%) 03/27/23 Court upholds decision to dismiss Pacira lawsuit against ASA 03/22/23 Pacira announces Yvonne Greenstreet to retire from Board 02/28/23 Pacira sees 2023 EXPAREL net sales $570M-$580M 02/23/23 Pacira, LPGA partner to raise awareness of non-opioid pain management solutions PCRX Pacira $39.93 / -0.15 (-0.37%) 03/03/23 Barclays Pacira price target lowered to $80 from $90 at Barclays 03/01/23 H.C. Wainwright Pacira price target raised to $71 from $69 at H.C. Wainwright 02/10/23 H.C. Wainwright Pacira price target lowered to $69 from $76 at H.C. Wainwright 01/31/23 Wedbush Pacira assumed with an Outperform at Wedbush PCRX Pacira $39.93 / -0.15 (-0.37%) 02/28/23 Pacira reports Q4 adjusted EPS 80c, consensus 83c 01/05/23 Pacira sees FY22 EPS 'at least' $2.50, consensus $2.77 11/03/22 Pacira reports Q3 adjusted EPS 64c, consensus 76c 10/13/22 Pacira reports preliminary Q3 revenue $167.5M, consensus $172.72M
Hot Stocks	Baltimore Orioles select Shift4 to process payments for ballpark concessions » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) "We're thrilled… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments rises 9.1% 01/17/23 Shift4 Payments partners with Real Salt Lake 11/22/22 Shift4 Payments falls -8.5% 11/07/22 Shift4 Payments rises 10.6% FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/16/23 Truist Shift4 Payments price target raised to $87 from $80 at Truist 03/01/23 RBC Capital Shift4 Payments price target raised to $80 from $70 at RBC Capital 03/01/23 Piper Sandler Shift4 Payments price target raised to $85 from $69 at Piper Sandler 03/01/23 DA Davidson Shift4 Payments price target raised to $80 from $65 at DA Davidson FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments sees FY23 revenue $2.5B-$2.7B. consensus $2.74B 02/28/23 Shift4 Payments reports Q4 adjusted EPS 47c, consensus 38c 02/27/23 Notable companies reporting before tomorrow's open 02/27/23 Notable companies reporting before tomorrow's open FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Fly Intel: Pre-market Movers 12/30/22 Buy/Sell: Wall Street's top 5 stock calls this week 12/29/22 What You Missed On Wall Street On Thursday 12/29/22 What You Missed On Wall Street This Morning FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/28/23 Shift4 Payments call volume above normal and directionally bullish 03/03/23 Shift4 Payments put volume heavy and directionally bearish 03/01/23 Shift4 Payments call volume above normal and directionally bullish
Hot Stocks	Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007 » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PGEN Precigen / + Precigen announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PGEN Precigen / + 01/24/23 Precigen reports results from Phase 1 PRGN-2012 study 01/11/23 Precigen CEO says will focus on clinical programs' path to licensure in 2023 12/12/22 Precigen announces 'positive' Phase 1 dose escalation data from PRGN-3006 study PGEN Precigen / + 01/30/23 Cantor Fitzgerald Precigen price target raised to $10 from $7 at Cantor Fitzgerald 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald PGEN Precigen / + 03/06/23 Precigen reports Q4 EPS (11c), consensus (10c) 11/09/22 Precigen reports Q3 EPS (4c), consensus 2c 25 Jan PGEN Precigen / + 01/27/23 Biotech Alert: Searches spiking for these stocks today 01/25/23 What You Missed On Wall Street On Wednesday 01/25/23 What You Missed On Wall Street This Morning 01/25/23 Fly Intel: Pre-market Movers PGEN Precigen / + 03/06/23 Precigen options imply 35.3% move in share price post-earnings 02/08/23 Largest borrow rate increases among liquid names

Hot Stocks	Third Harmonic Bio expects cash to fund requirements through next 12 months » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/16/22 Jefferies Third Harmonic Bio downgraded to Hold from Buy at Jefferies 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 08:06 Today Third Harmonic Bio reports 2022 EPS ($2.62), consensus ($2.39) 15 Sep THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning
Recommendations	Biolase price target lowered to $1 from $5 at Maxim » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 BIOL Biolase / + Maxim analyst Anthony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BIOL Biolase / + 01/04/23 Sonendo unit files patent infringement lawsuit against Biolase BIOL Biolase / + 01/20/23 Lake Street Biolase assumed with a Buy at Lake Street 11/11/22 Maxim Biolase price target lowered to $5 from $10 at Maxim 05/20/22 Lake Street Biolase initiated with a Buy at Lake Street BIOL Biolase / + 03/28/23 Biolase sees Q1 revenue over $10.0M, consensus $12.23M 03/28/23 Biolase reports Q4 EPS ($1.28), consensus (64c) 01/18/23 Biolase targets revenue growth by at least 25% in 2023, consensus $55.06M 01/18/23 Biolase sees 2022 revenue $48.4M-$48.8M, consensus $47.58M
Hot Stocks	ProQR announces initial pipeline targets, highlights Axiomer platfotform » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) ProQR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 03/14/23 ProQR Therapeutics announces successful defense of Axiomer patent pending 03/07/23 ProQR Therapeutics to present on Axiomer RNA editing technology platform 12/22/22 Eli Lilly, ProQR expand genetic medicines licensing and collaboration agreement 12/22/22 Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 03/10/23 Stifel Stifel says SVB fallout 'appears limited' across firm's biotech coverage 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 12/23/22 Raymond James ProQR Therapeutics price target raised to $5 from $2 at Raymond James 12/22/22 JMP Securities ProQR Therapeutics shares remain 'fairly valued,' says JMP Securities PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 11/09/22 ProQR Therapeutics reports Q3 EPS (EUR 0.34) vs (EUR 0.22) last year PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 12/22/22 Fly Intel: Pre-market Movers 10:00 Today ProQR Therapeutics - PRQR
Hot Stocks	EzFill and SaverOne 2014 launch driving safety pilot program in Florida » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 SVRE SaverOne 2014 $1.15 / +0.02 (+1.77%) , EZFL EzFill / + EzFill (EZFL) announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings SVRE EZFL SVRE SaverOne 2014 $1.15 / +0.02 (+1.77%) 03/23/23 SaverOne 2014 signs agreement with Moviley Dror involving 150 delivery trucks 03/08/23 SaverOne 2014 signs agreement with Electra Afikim 01/19/23 SaverOne 2014's safe driving system adopted by Israeli supermarket Shufersal 01/17/23 SaverOne 2014 collaborating with Israeli auto importer for safe driving system EZFL EzFill / + 03/03/23 EzFill adds 10 fleet accounts in February 02/23/23 EzFill named Arbour to board of directors 02/21/23 EzFill signs agreement with South Florida Motorsports 01/30/23 EzFill to launch EzFill NOW Program EZFL EZFL EzFill / + 02/10/23 EzFill reports preliminary Q4 revenue $4.9M vs. $2M last year 11/08/22 EzFill reports Q3 EPS (15c) vs. (13c) last year
Earnings	Third Harmonic Bio reports 2022 EPS ($2.62), consensus ($2.39) » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) "Given the promising… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/16/22 Jefferies Third Harmonic Bio downgraded to Hold from Buy at Jefferies 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley 15 Sep THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning

Events

Earnings calls, analyst events, roadshows and more

BTMD
Today at 08:30

Biote - BTMD Conference Calls
GLYC
Today at 08:30

GlycoMimetics - GLYC Conference Calls
MINM
Today at 08:30

Minim - MINM Conference Calls
BLUE
Today at 08:30

Bluebird Bio - BLUE Conference Calls
UNF
Today at 09:00

UniFirst - UNF Conference Calls
RDW
Today at 09:00

Redwire - RDW Conference Calls
BOSC
Today at 09:00

BOS Better Online Solutions - BOSC Conference Calls
IBEX
Today at 09:00

Ibex - IBEX Conference Calls
CLH
Today at 09:00

Clean Harbors Firm Sponsored Meetings

Virtual Meeting
PAYX
Today at 09:30

Paychex - PAYX Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	YGF X YGF YanGuFang IPO Managers: EF Hutton Priced at: $4.00 2M Shares ZJYL X ZJYL Jin Medical IPO Managers: Prime Number Priced at: $8.00 1M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	SYT X SYT Syla Technologies IPO Managers: Boustead $8.00 1.875M Shares
Fri	No deals

View All Syndicate Announcements »

NASDAQ market internals summary

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access